Document Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: A comparison of colorimetric and fluorescence imaging
Document Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors
Document Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis
Document Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review
Document Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly
Document Clinical–pathologic and morbidity analyses of Types 2 and 3 abdominal radical hysterectomy for cervical cancer
Document Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third- line therapy in patients with platinum-refractory or -resistant ovarian cancer
Document Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models
Document A Detailed Study of Patients and Tumor Characteristics of Epithelial Ovarian Cancer in Saudi Women
Document Metastatic Choriocarcinoma in a Viable Intrauterine Pregnancy Treated with EMA-CO in the Third Trimester
Document Malignant melanoma arising in a mature teratoma: A case report with review of the recent literature
Document Use of pegylated liposomal doxorubicin in the management of platinum- sensitive recurrent ovarian cancer: current concepts
Document A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
Document Robotic-Assisted Hysterectomy for Endometrial Cancer Compared With Traditional Laparoscopic and Laparotomy Approaches
Document Synergistic cytotoxicity of interferon-2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy
